Document is current

Article History

Received: 26 February 2025

Accepted: 24 May 2025

First Online: 19 June 2025

Declarations

:

: SS has received grants and/or contracted clinical trials from Taiho, Eisai, Chugai, Takeda, MSD, Astra Zeneca, Daiichi Sankyo, Gilead, Eli Lilly, and Sanofi; honoraria from Chugai, Kyowa Kirin, MSD, Novartis, Eisai, Takeda, Daiichi Sankyo, Eli Lilly, Astra Zeneca, Pfizer, Taiho, Ono, Nipponkayaku, Gilead, and Exact Sciences; participation on a data safety monitoring board or advisory board for Chugai/Roche, Astra Zeneca, Eli Lilly, Pfizer, Kyowa Kirin, Daiichi Sankyo, and MSD; and executive board membership of Japan Breast Cancer Research Group, Japan Breast Cancer Society, Japanese Society of Medical Oncology, and Breast International Group. The other authors declare that they have no conflicts of interest. All grants and fees were for work unrelated to the submitted work. The authors have no other competing interests or relevant affiliations with any organization or entity with the subject matter or materials discussed in the manuscript apart from those disclosed.

: This study was approved by the Research Ethics Committee of Fukushima Medical University (registration number: REC2023--230) and the Information Utilization Review Board of C-CAT (CDU2024--022 N, 2024/1).